A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
Study sponsor: Rhythm Pharmaceuticals, Inc. · RYTM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-05-07Estimated
Enrollment · participants111Actual
Source updated2026-10-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.